---
title: "Moderna 旗下實驗性流感疫苗後期試驗結果正面"
description: "Moderna 宣佈其基於 mRNA 的實驗性流感疫苗在後期試驗中顯示出比現有疫苗更強的免疫反應，股價盤前上漲逾 3%。公司計劃在今年稍後重新提交聯合疫苗的申請，並申請獨立流感疫苗的批准，若獲監管機構批准，將推動聯合疫苗的研發。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/246684717.md"
published_at: "2025-06-30T12:38:09.000Z"
---

# Moderna 旗下實驗性流感疫苗後期試驗結果正面

> Moderna 宣佈其基於 mRNA 的實驗性流感疫苗在後期試驗中顯示出比現有疫苗更強的免疫反應，股價盤前上漲逾 3%。公司計劃在今年稍後重新提交聯合疫苗的申請，並申請獨立流感疫苗的批准，若獲監管機構批准，將推動聯合疫苗的研發。

Moderna(MRNA.US) 週一表示，其基於 mRNA 的實驗性流感疫苗在後期試驗中顯示比目前可用的疫苗更強的免疫反應，為該產品以及該公司單獨的流感和新冠疫苗組合的發展鋪路。該股股價盤前升逾 3%。

公司表示，在新數據下，計劃在今年稍後重新提交聯合疫苗的申請，並申請批准其獨立的流感疫苗。若監管機構批准流感疫苗，該公司就可以推動聯合疫苗的研發。

### Related Stocks

- [MRNA.US - Moderna](https://longbridge.com/zh-HK/quote/MRNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike | EMA's CHMP recommended marketing authorisation for Moderna's Mnexspike for COVID-19 prevention in individuals aged 12 an | [Link](https://longbridge.com/zh-HK/news/269540340.md) |
| Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts | Moderna has secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to fund its bird | [Link](https://longbridge.com/zh-HK/news/270158044.md) |
| Fibonacci’s 61.8% in Gold - Third Time Not-So-Lucky | Fibonacci’s 61.8% in Gold - Third Time Not-So-Lucky | [Link](https://longbridge.com/zh-HK/news/276474128.md) |
| Cruise operator Carnival to unify dual listing | Carnivalannounced plans to unify its dual listings in New York and London and redomicile to Bermuda. The UK-listed Carni | [Link](https://longbridge.com/zh-HK/news/276491689.md) |
| Saba Capital Management Submitted Notice To Blue Owl Capital Corporation II On February 17, 2026 | Saba Capital Management submitted a notice to Blue Owl Capital Corporation II on February 17, 2026, indicating its inten | [Link](https://longbridge.com/zh-HK/news/276478016.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。